TY - JOUR T1 - Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study JO - PharmacoEconomics PY - 2021/06/19 AU - Pennington B AU - Alshreef A AU - Flight L AU - Metry A AU - Poku E AU - Hykin P AU - Sivaprasad S AU - Prevost AT AU - Vasconcelos JC AU - Murphy C AU - Kelly J et al ED - DO - DOI: 10.1007/s40273-021-01057-y PB - Springer Science and Business Media LLC Y2 - 2025/03/17 ER -